Project Grant R33CA291185
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$336K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Tennessee, USA
Similar Awards
This $670,147 federal Project Grant awarded by the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to improve the clinical sensitivity of circulating tumor DNA (ctDNA) liquid biopsies for cancer detection and management. The award to Vanderbilt University Medical Center aims to: Elucidate the role of the RNA binding protein SAM68 in mediating cell-free DNA (cfDNA) release from cells; Optimize pharmacologic approaches...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) aims to understand the mechanisms underlying biased agonism in receptor tyrosine kinases and explore new approaches for their therapeutic targeting in cancer. The $249,000 award, spanning January 2025 to December 2027, supports the recipient, Vanderbilt University, in conducting advanced microscopy-based analyses of receptor activation kinetics in living cells. The goal is to elucidate how the...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a novel approach to detect and report on the expression of multiple cytokine genes simultaneously in tissues. The $234,919 award to Yale University, to be completed by August 31, 2027, will combine CRISPR-mediated transcriptional activation with genetically-encoded fluorescent reporters to enable the dynamic, high-sensitivity and multiplexed monitoring of cytokine...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $465,028 to North Carolina State University to advance functional mass spectrometry imaging (FMSI) methodology for monitoring dynamic physiological processes in tissues. The project aims to: Evaluate different protocols for administering isotopologue substrates to improve sensitivity and extend the observable metabolic window using FMSI. Demonstrate FMSI's ability to detect tissue...
This National Science Foundation (NSF) Project Grant award for $380,074, awarded on September 1, 2024, aims to develop a platform for instrument-free, easy-to-interpret quantitative analysis of molecular biomarkers. The project will produce a general methodology adaptable to a range of molecular targets, including potential new agents. The key products to be delivered include: A "yes/no" output for quantitative measurement, enabled through stoichiometry and negative cooperativity-based...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
This $440,287 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is funding the development of a simplified, accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. The goal is to democratize cancer biobanking by enabling lower-resource institutes to conduct comprehensive molecular analyses on smaller tumor samples, including genomic sequencing, gene expression profiling, and protein...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Assayquant Technologies, Inc. provides $1,093,104 to develop and commercialize a suite of biosensor peptides for the quantitative, high-throughput measurement of oncogenic protein kinases in cell and tissue samples. The key products to be developed and validated under this 2-year award include: Lysate-compatible sensor peptides for measuring activity of mitogen-activated protein kinases (MAPKs)...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...